Form D · Pharmaceuticals

DTx Pharma, Inc.

San Diego, CA · CIK 0001715954

Offering snapshot reported Mar 10, 2021 · SEC filing

Reported sold
$100M
Offering amount: $100M
Investors reported
22
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 26, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 10, 2021Initial$100,205,508No comparison22SEC filing
Jul 6, 2020Initial$200,000No comparison1SEC filing
Sep 20, 2019Amendment$12,000,000$6,500,000vs Apr 23, 201960SEC filing
Apr 23, 2019Initial$5,500,000No comparison60SEC filing
Jun 15, 2018Amendment$1,000,000$975,000vs Aug 30, 201715SEC filing
Aug 30, 2017Initial$25,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-391787
Total amount sold includes $205,523.29 of cancellation of indebtedness and $99,999,985.24 of new cash.

Source: Form D, filed Mar 10, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Andrew Adams Director
Daniel Becker Director
Jeffrey Friedman Director, Executive
John Grundy Director
Matthew Hammond Director
John Rundy Director
Tim Scott Director
Arthur Suckow Director, Executive
Niki Upper Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
10655 Sorrento Valley Rd #100
San Diego, CA, 92121